Patents by Inventor Leah Cleary

Leah Cleary has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS
    Publication number: 20230257359
    Abstract: Disclosed herein are certain 4-arylquinazoline derivatives of Formula (I) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Application
    Filed: June 9, 2021
    Publication date: August 17, 2023
    Inventors: Leah CLEARY, Melissa FLEURY, Zhonghua PEI, Richard STEEL
  • QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS
    Publication number: 20230227409
    Abstract: Disclosed herein are certain quinolinone derivatives of Formula (A) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Application
    Filed: June 9, 2021
    Publication date: July 20, 2023
    Inventors: Leah CLEARY, Melissa FLEURY, Zhonghua PEI
  • 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS
    Publication number: 20220106276
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Application
    Filed: December 9, 2019
    Publication date: April 7, 2022
    Inventors: Muzaffar ALAM, Leah CLEARY, Melissa FLEURY, Zhonghua PEI, Richard STEEL, James SUTTON, John E. KNOX, Zachary E. R. NEWBY
  • 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
    Patent number: 11130759
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: September 28, 2021
    Assignee: IDEAYA BIOSCIENCE, INC.
    Inventors: Muzaffar Alam, Leah Cleary, Melissa Fleury, Zhonghua Pei, Richard Steel, James Sutton, John E. Knox, Zachary E. R. Newby
  • 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
    Patent number: 11084798
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: August 10, 2021
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Muzaffar Alam, Leah Cleary, Melissa Fleury, Zhonghua Pei, Richard Steel, James Sutton, John E. Knox, Zachary E. R. Newby
  • 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
    Patent number: 11046691
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: June 29, 2021
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Muzaffar Alam, Leah Cleary, Melissa Fleury, Zhonghua Pei, Richard Steel, James Sutton, John E. Knox, Zachary E. R. Newby